LONDON and SAO PAULO, March 09, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies, is pleased to announce that the Brazil regulatory agency for medical devices, namely, ANVISA (Agência Nacional de Vigilância Sanitária) has approved Claritas Neuroclould™ for supply in Brazil.

LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specialising in state-of-the-art image enhancement, noise reduction, segmentation and quantification, and related AI technologies, is pleased to announce that the Australian regulatory agency for medicines and medical devices, namely, the Therapeutic Goods Administration (TGA) has approved the software device, Claritas iPET™ for supply in Australia.

SINGAPORE and LONDON and NEW YORK, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp (“ISC”), specialising in state-of-the-art image enhancement and precision AI software solutions for urology and gastroenterology, is pleased to announce that CystoSmart™ has received regulatory clearance from Health Sciences Authority (HSA), the National Regulatory Agency for medical products and devices in Singapore.

OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation (ISC) to develop Artificial Intelligence (AI) software with blue light cystoscopy (BLC®). Initial testing shows promising performance results. In the current development phase, Photocure and ISC are collaborating to develop an AI software which can support the physician in real-time during blue light cystoscopy, improving early-stage bladder cancer detection, diagnosis, and resection completeness.

NEW YORK and LONDON and SAO PAULO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed Brazil”), a subsidiary of UK-based Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company specializing in image processing and quantification for the nuclear medicine imaging industry, is pleased to announce that it has secured regulatory clearance from the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária) to market its cutting-edge technology, iPETcertum™ in Brazil.

LONDON and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art signal processing, quantification and AI technologies for the nuclear medicine industry, is pleased to announce that iPETcertum™, a software device for enhancement, automated segmentation and quantification in PET (Positron Emission Tomography) scans has received FDA clearance.

LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image enhancement, reconstruction, and AI solutions for the medical industry, is pleased to announce that it has secured regulatory clearance from the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária) to market Claritas CystoSmart™ in Brazil.

NEW YORK and LONDON and SAO PAOLO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Claritas NucMed Tech Brazil S.A. (“Claritas NucMed Brazil”), a subsidiary of UK-based Claritas NucMed Technologies Ltd (“Claritas NucMed”), a company specializing in image processing and quantification for the nuclear medicine imaging industry, is pleased to announce that it has secured regulatory clearance from the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária) to market Claritas iPET™ in Brazil.

LONDON and SAO PAULO, May 13, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image processing, segmentation, and AI solutions for the medical industry, is pleased to announce that it has finalized a partnership with Qubiotech Health Intelligence S.L. (“Qubiotech”), a company with expertise in analysis, localization and quantification of brain biomarkers in MRI, PET and SPECT images.

HONG KONG and LONDON, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”), a healthcare technology company specializing in medical image enhancement and Artificial Intelligence (AI) assisted diagnostic tools, is pleased to announce it has developed, ReDisys™, an AI tool for detecting cancer in CT (Computed Tomography) images of the kidney.

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision AI software solutions for gastroenterology and urology, is pleased to announce the completion of its AI platform for gastroenterology, namely, Helga AI-GEP™. The platform will offer computer aided devices for detection, classification and characterization of lesions and tissue irregularities in the colon (colon cancer) and the upper gastrointestinal tract (esophageal and gastric cancer).

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology. Combining the research capabilities and clinical expertise of Mayo Clinic, with the technology of Intelligent Scopes in image enhancement and expertise in development of precision AI diagnostic tools, this collaboration aims to deliver software tools that aid urologists in the detection, surgery, and post-treatment surveillance.